SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Nexalin Technology reports secondary analysis improvements in Alzheimer’s trial data

Nexalin Technology said further ADAS-Cog data analysis from its randomized, sham-controlled trial found improvements tied to memory domains in Alzheimer’s patients. The Company plans to use ADAS-Cog subscale results for a planned U.S. Alzheimer’s pilot study.

NXL

This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.

Related stories